OR:EURONEXT PARISL'Oreal S.A. Analysis
Data as of 2026-05-20 - not real-time
$36.05
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
OR Royalties Inc. trades at $36.05, well above its discounted cash flow fair value of $15.86, suggesting a significant premium. The stock’s forward P/E of 21.3 and price‑to‑book of 4.71 further underscore the elevated valuation relative to peers. Despite the premium, the company delivers exceptional profitability with a gross margin of 96.7% and an operating margin of 85.4%. Revenue has surged 87% year‑over‑year, and cash generation remains robust, evidenced by $27.1 m of operating cash flow and a low debt‑to‑equity of 0.315. The dividend yield sits at a modest 0.73% with a payout ratio of only 16%, indicating ample capacity to sustain the payout. Technical indicators are mixed: RSI at 41 points to neutral momentum, while a bearish MACD histogram and price hovering near the $34.73 support level raise short‑term downside concerns.
Market sentiment is in “Extreme Greed” territory (Fear & Greed Index 90.29), which together with a 30‑day volatility of 46% amplifies the risk of a correction. The stock’s beta of 0.98 suggests market‑aligned price movements, and volume has remained stable, limiting immediate liquidity pressure. Given the strong cash position, low leverage, and high ROE of 19%, the underlying business fundamentals remain solid for the medium to long term. However, the current overvaluation and bearish technical signal counsel caution for investors seeking short‑term gains. A balanced approach would be to hold the position while monitoring price action around the support zone and any shifts in valuation multiples. If the market re‑prices the royalty assets closer to intrinsic value, OR could present a compelling upside for patient investors.
Market sentiment is in “Extreme Greed” territory (Fear & Greed Index 90.29), which together with a 30‑day volatility of 46% amplifies the risk of a correction. The stock’s beta of 0.98 suggests market‑aligned price movements, and volume has remained stable, limiting immediate liquidity pressure. Given the strong cash position, low leverage, and high ROE of 19%, the underlying business fundamentals remain solid for the medium to long term. However, the current overvaluation and bearish technical signal counsel caution for investors seeking short‑term gains. A balanced approach would be to hold the position while monitoring price action around the support zone and any shifts in valuation multiples. If the market re‑prices the royalty assets closer to intrinsic value, OR could present a compelling upside for patient investors.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD histogram
- Price trading above DCF fair value
- High short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong cash flow and low debt
- Sustainable dividend with low payout ratio
- Valuation gap remains wide
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Stable royalty income streams
- High ROE and profit margins
- Potential re‑rating of intrinsic value
Key Metrics & Analysis
Financial Health
Revenue Growth87.30%
Profit Margin78.09%
P/E Ratio26.9
ROE18.91%
ROA10.28%
Debt/Equity0.32
P/B Ratio4.7
Op. Cash Flow$271.4M
Free Cash Flow$82.3M
Technical Analysis
TrendNeutral
RSI41.0
Support$34.73
Resistance$40.76
MA 20$37.75
MA 50$38.33
MA 200$37.24
MACDBearish
VolumeStable
Fear & Greed Index90.29
Valuation
Fair Value$15.86
Target Price$57.00
Upside/Downside58.11%
GradeOvervalued
TypeGrowth
Dividend Yield0.73%
Risk Assessment
Beta0.98
Volatility46.33%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.